experimental group:pembrolizumab

2 trials

Sponsors

Chinese Academy of Medical Sciences Cancer Hospital, The First Affiliated Hospital of University of Science and Technology of China

Conditions

esophageal squamous carcinomamelanoma

Phase 2

A single center, single arm, prospective study: efficacy and safety of adjuvant therapy with pembrolizumab in high-risk postoperative acral malignant melanoma

Active, not recruitingChiCTR2200064502

Chinese Academy of Medical Sciences Cancer Hospitalmelanoma

Start: 2022-11-01Updated: 2023-05-15

Phase 4

A one-arm, open study of parbolizumab combined with chemotherapy for conversion therapy in patients with esophageal squamous cell carcinoma with cervical lymph node metastasis

RecruitingChiCTR2300069228

The First Affiliated Hospital of University of Science and Technology of Chinaesophageal squamous carcinoma

Start: 2023-03-10Updated: 2023-05-29